This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
by Urmimala Biswas
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
TXGNegative Net Change DOCSPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-growth earnings-outlook healthcare medical medical-devices
3 MedTech Stocks Poised to Gain in 2026 From the AI Boom
by Sridatri Sarkar
AI is reshaping MedTech, and Stryker, Tempus AI and GE HealthCare are emerging as key players leveraging AI across surgery, diagnostics and imaging.
SYKPositive Net Change NVDANegative Net Change GEHCNegative Net Change TEMPositive Net Change
artificial-intelligence medical medical-devices
Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now?
by Zacks Equity Research
PAHC rides on strong Animal Health momentum, vaccine growth and emerging market demand, even as macro and competitive risks linger.
ILMNNegative Net Change PODDPositive Net Change PAHCPositive Net Change BTSGNegative Net Change
medical medical-devices
TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio
by Zacks Equity Research
Thermo Fisher expands its Gibco Bacto CD portfolio with new formulations aimed at boosting E. coli-based plasmid DNA and protein production efficiency.
TMONegative Net Change ILMNNegative Net Change PODDPositive Net Change BTSGNegative Net Change
medical medical-devices
Tempus AI Near $75 Target? Valuation, Upside and Risks
by Urmimala Biswas
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
TXGNegative Net Change DOCSPositive Net Change TEMPositive Net Change
artificial-intelligence healthcare medical medical-devices
Abbott Gains From Lingo CGM's Expansion on Android Platform
by Zacks Equity Research
ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.
ABTNegative Net Change BSXNegative Net Change ISRGNegative Net Change ATRCNegative Net Change
medical medical-devices
BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care
by Zacks Equity Research
Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.
BSXNegative Net Change BAXNegative Net Change ISRGNegative Net Change MEDPNegative Net Change
medical medical-devices
4 Medical Device Stocks to Buy for Healthy Returns in 2026
by Moumi Mondal
ISRG, PODD, BSX and IDXX lead medtech innovation with AI, robotics and diagnostics for growth in 2026.
BSXNegative Net Change ISRGNegative Net Change IDXXPositive Net Change PODDPositive Net Change
medical medical-devices
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform
by Zacks Equity Research
AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.
BSXNegative Net Change ISRGNegative Net Change ATRCNegative Net Change MEDPNegative Net Change
medical medical-devices
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
by Zacks Equity Research
CeriBell gains FDA clearance for its continuous delirium monitoring solution, boosting its AI-driven EEG platform and expanding its role in critical care.
BSXNegative Net Change ATRCNegative Net Change PAHCPositive Net Change CBLLNegative Net Change
medical medical-devices
Should You Buy Southern Missouri Bancorp (SMBC) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SMBCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hims & Hers Expands Weight-Management Program to the United Kingdom
by Zacks Equity Research
HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.
BSXNegative Net Change ISRGNegative Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices
What Is Driving Hologic's Strength in the US Diagnostics Market?
by Moumi Mondal
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
ABTNegative Net Change RHHBYPositive Net Change HOLXNegative Net Change
medical medical-devices
Hims & Hers Expands Its Technology-Driven Personalized Virtual Care
by Debanjana Dey
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
TDOCNegative Net Change HIMSPositive Net Change DOCSPositive Net Change
medical medical-devices
ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries
by Zacks Equity Research
Intuitive Surgical broadens its da Vinci SP system with FDA clearance for three new surgeries, expanding its role in minimally invasive care.
ISRGNegative Net Change EDAPNegative Net Change VCYTPositive Net Change AORTPositive Net Change
medical medical-devices
First Financial Bancorp (FFBC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
FFBCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?
by Indrajit Bandyopadhyay
Intuitive Surgical grapples with a GLP-1-driven bariatric slump but leans on strong general surgery gains and rising da Vinci 5 adoption.
MDTNegative Net Change ISRGNegative Net Change TFXNegative Net Change
medical medical-devices
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
by Zacks Equity Research
WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.
BSXNegative Net Change ISRGNegative Net Change WSTNegative Net Change MEDPNegative Net Change
medical medical-devices
Should You Continue to Hold EW Stock in Your Portfolio?
by Zacks Equity Research
Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
EWNegative Net Change ILMNNegative Net Change PODDPositive Net Change BTSGNegative Net Change
medical medical-devices
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
by Moumi Mondal
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change
medical medical-devices
BEAT Secures FDA Nod for First Cable-Free At-Home 12-Lead ECG System
by Zacks Equity Research
HeartBeam's FDA clearance for its cable-free at-home 12-lead ECG marks a pivotal step toward commercialization and broader cardiac-care adoption.
BSXNegative Net Change ISRGNegative Net Change BEATNegative Net Change MEDPNegative Net Change
medical medical-devices
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.
BSXNegative Net Change ISRGNegative Net Change FMSPositive Net Change MEDPNegative Net Change
medical medical-devices
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
by Zacks Equity Research
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.
ISRGNegative Net Change VCYTPositive Net Change PLSEPositive Net Change AORTPositive Net Change
medical medical-devices
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
Cencora's U.S. Healthcare Solutions strength, RCA gains, and raised FY25 guidance underscore its accelerating growth momentum.
ISRGNegative Net Change CORNegative Net Change VCYTPositive Net Change MEDPNegative Net Change
medical medical-devices
Is it Worth Retaining NEOG Stock in Your Portfolio for Now?
by Zacks Equity Research
Neogen leans on new product launches and 3M Food Safety integration to offset solvency strains and macro pressures.
OMCLNegative Net Change ILMNNegative Net Change NEOGNegative Net Change BTSGNegative Net Change
medical medical-devices